Association of survival and genomic mutation signature with immunotherapy in patients with hepatocellular carcinoma

Abstract

Immunotherapy showed longer OS and PFS than conventional therapy among HCC patients, especially patients with a low mutation risk score. The nomogram based on genomic and clinical characteristics is effective in predicting survival of HCC patients undergoing immune checkpoint inhibitor.